Currently, tumour response and treatment benefit are determined using radiographic imaging and PSA assessment, but this may result in patient over-treatment and can be confounded by an apparent initial worsening that is in fact due to a flare secondary to bone remodelling at responding metastatic sites. Here, KLK3 is linked to neoplasm.